BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Z, Zhou M, Wu Y, Li Z, Liu X, Wu L, Liang D. ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECs. Mol Ther Nucleic Acids 2019;17:198-209. [PMID: 31261034 DOI: 10.1016/j.omtn.2019.05.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Son JS, Park C, Lee G, Park JY, Kim HJ, Kim G, Chi KY, Woo D, Han C, Kim SK, Park H, Kim D, Kim J. Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121429] [Reference Citation Analysis]
2 Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL, Rawal RM, Ramakrishna S, Singh V. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. J Control Release 2022:S0168-3659(22)00080-3. [PMID: 35149141 DOI: 10.1016/j.jconrel.2022.02.005] [Reference Citation Analysis]
3 Qiu L, Xie M, Zhou M, Liu X, Hu Z, Wu L. Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCs. Front Cell Dev Biol 2021;9:630353. [PMID: 33644070 DOI: 10.3389/fcell.2021.630353] [Reference Citation Analysis]
4 Rose M, Gao K, Cortez-Toledo E, Agu E, Hyllen AA, Conroy K, Pan G, Nolta JA, Wang A, Zhou P. Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A. Stem Cells Transl Med 2020;9:686-96. [PMID: 32162786 DOI: 10.1002/sctm.19-0261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zhou M, Hu Z, Zhang C, Wu L, Li Z, Liang D. Gene Therapy for Hemophilia A: Where We Stand. Curr Gene Ther 2020;20:142-51. [PMID: 32767930 DOI: 10.2174/1566523220666200806110849] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Landmesser U, Poller W, Tsimikas S, Most P, Paneni F, Lüscher TF. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Eur Heart J 2020;41:3884-99. [PMID: 32350510 DOI: 10.1093/eurheartj/ehaa229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 18.0] [Reference Citation Analysis]
7 Ding C, Zhang C, Kopp R, Kuney L, Meng Q, Wang L, Xia Y, Jiang Y, Dai R, Min S, Yao WD, Wong ML, Ruan H, Liu C, Chen C. Transcription factor POU3F2 regulates TRIM8 expression contributing to cellular functions implicated in schizophrenia. Mol Psychiatry 2021;26:3444-60. [PMID: 32929213 DOI: 10.1038/s41380-020-00877-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jair Lara-navarro I, Rebeca Jaloma-cruz A. Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. Tohoku J Exp Med 2022;256:197-207. [DOI: 10.1620/tjem.256.197] [Reference Citation Analysis]
9 Luo S, Li Z, Dai X, Zhang R, Liang Z, Li W, Zeng M, Su J, Wang J, Liang X, Wu Y, Liang D. CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A. Front Cell Dev Biol 2021;9:672564. [PMID: 34485274 DOI: 10.3389/fcell.2021.672564] [Reference Citation Analysis]
10 Chen Y, Wen R, Yang Z, Chen Z. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders. Gene Ther 2021. [PMID: 33750926 DOI: 10.1038/s41434-021-00247-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]